The U.S. Drug Enforcement Administration (DEA) plans to reclassify marijuana as a less dangerous drug, recognizing its medical uses and acknowledging its lower potential for abuse compared to more hazardous substances. This proposal, which is yet to be reviewed by the White House Office of Management and Budget (OMB), does not fully legalize recreational use but would shift marijuana from a Schedule I to a Schedule III classification.
The DEA's decision marks a significant change in U.S. drug policy, highlighting a shift in how marijuana is perceived in terms of medical utility and abuse potential.
Marijuana is currently classified as a Schedule I drug, indicating no accepted medical use and a high potential for abuse, on par with heroin and LSD. The proposed reclassification to Schedule III, which includes drugs like ketamine and some steroids, suggests recognized medical uses and a lower abuse potential.
-The proposal is pending review by the OMB, after which it will be open to public comments. This will be followed by a judicial review before the final rule is published, marking the completion of the regulatory process.
– While this change won’t legalize recreational marijuana, it will likely ease restrictions on research and soften penalties associated with its use and possession, influencing various aspects of national drug policy, public health, and criminal justice.